Charles Schwab Investment Management Inc. Grows Holdings in DexCom, Inc. (NASDAQ:DXCM)

Charles Schwab Investment Management Inc. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 11.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,734,155 shares of the medical device company’s stock after purchasing an additional 288,381 shares during the period. Charles Schwab Investment Management Inc.’s holdings in DexCom were worth $183,298,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Jennison Associates LLC boosted its holdings in DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after buying an additional 353,019 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its stake in shares of DexCom by 14.4% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,617,001 shares of the medical device company’s stock worth $183,336,000 after buying an additional 203,043 shares during the last quarter. Finally, Rathbones Group PLC raised its holdings in DexCom by 5.8% in the second quarter. Rathbones Group PLC now owns 1,401,802 shares of the medical device company’s stock valued at $158,936,000 after acquiring an additional 76,727 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several recent analyst reports. Barclays decreased their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a report on Monday, July 29th. Stifel Nicolaus upped their price objective on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $104.59.

DexCom Trading Down 2.2 %

DexCom stock opened at $72.83 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $28.45 billion, a price-to-earnings ratio of 43.61, a PEG ratio of 2.28 and a beta of 1.17. The firm has a 50-day moving average price of $70.61 and a two-hundred day moving average price of $89.83.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.